Efficacy of secnidazole-diminazene aceturate combination therapy in the late treatment of Trypanosoma brucei brucei infection in dogs

Detalhes bibliográficos
Autor(a) principal: Eke, Ifeanyi Gabriel
Data de Publicação: 2020
Outros Autores: Ezeh, Ikenna Onyema, Ezeudu, Terry Adaeze, Eze, Ukamaka Uchenna, Anaga, Aruh Ottah, Onyeyili, Patrick Azubuike
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Brazilian Journal of Pharmaceutical Sciences
Texto Completo: https://www.revistas.usp.br/bjps/article/view/181418
Resumo: This study evaluated the efficacy of combination therapy of secnidazole-diminazene aceturate (SEC‑DA) in late treatment of dogs experimentally infected with relapsing strain of Trypanosoma brucei brucei. Fifteen dogs were randomly assigned to 5 groups (A – E) of 3 per group. Group A (uninfected untreated), B (infected untreated), C (infected and treated with DA (3.5 mg/kg) IM stat), D (infected and treated with secnidazole (SEC) (100 mg/kg) orally for 5 days and DA (3.5 mg/kg) IM stat), E (infected and treated with SEC (200 mg/kg) orally for 5 days and DA (3.5 mg/kg) IM stat). Dogs were infected intraperitoneally with 5 x 105 trypanosomes and treatment started 14 days post-infection. Data on parasitaemia, hematology and rectal temperature were recorded. Parasitaemia cleared within 3 days in all the SEC-DA treated dogs and there was no relapse parasitaemia. Parasitaemia did not clear in DA monotherapy dogs. All the SEC-DA treated dogs showed significantly (P < 0.05) higher leucocyte counts, red blood cell count, packed cell volume, hemoglobin concentration and lower rectal temperature than DA monotherapy. It was, therefore, concluded that SEC-DA combination is therapeutically more efficacious than DA monotherapy in the late treatment of T.b. brucei infection in dogs.
id USP-31_35df2b65953df7eb94aa8ba904578998
oai_identifier_str oai:revistas.usp.br:article/181418
network_acronym_str USP-31
network_name_str Brazilian Journal of Pharmaceutical Sciences
repository_id_str
spelling Efficacy of secnidazole-diminazene aceturate combination therapy in the late treatment of Trypanosoma brucei brucei infection in dogsSecnidazoleDiminazene aceturateCombination therapyTrypanosomosisDogsRelapseThis study evaluated the efficacy of combination therapy of secnidazole-diminazene aceturate (SEC‑DA) in late treatment of dogs experimentally infected with relapsing strain of Trypanosoma brucei brucei. Fifteen dogs were randomly assigned to 5 groups (A – E) of 3 per group. Group A (uninfected untreated), B (infected untreated), C (infected and treated with DA (3.5 mg/kg) IM stat), D (infected and treated with secnidazole (SEC) (100 mg/kg) orally for 5 days and DA (3.5 mg/kg) IM stat), E (infected and treated with SEC (200 mg/kg) orally for 5 days and DA (3.5 mg/kg) IM stat). Dogs were infected intraperitoneally with 5 x 105 trypanosomes and treatment started 14 days post-infection. Data on parasitaemia, hematology and rectal temperature were recorded. Parasitaemia cleared within 3 days in all the SEC-DA treated dogs and there was no relapse parasitaemia. Parasitaemia did not clear in DA monotherapy dogs. All the SEC-DA treated dogs showed significantly (P < 0.05) higher leucocyte counts, red blood cell count, packed cell volume, hemoglobin concentration and lower rectal temperature than DA monotherapy. It was, therefore, concluded that SEC-DA combination is therapeutically more efficacious than DA monotherapy in the late treatment of T.b. brucei infection in dogs.Universidade de São Paulo. Faculdade de Ciências Farmacêuticas2020-12-09info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://www.revistas.usp.br/bjps/article/view/18141810.1590/s2175-97902019000318042Brazilian Journal of Pharmaceutical Sciences; Vol. 56 (2020); e18042Brazilian Journal of Pharmaceutical Sciences; v. 56 (2020); e18042Brazilian Journal of Pharmaceutical Sciences; Vol. 56 (2020); e180422175-97901984-8250reponame:Brazilian Journal of Pharmaceutical Sciencesinstname:Universidade de São Paulo (USP)instacron:USPenghttps://www.revistas.usp.br/bjps/article/view/181418/168347Copyright (c) 2020 Brazilian Journal of Pharmaceutical Scienceshttp://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessEke, Ifeanyi Gabriel Ezeh, Ikenna Onyema Ezeudu, Terry Adaeze Eze, Ukamaka Uchenna Anaga, Aruh Ottah Onyeyili, Patrick Azubuike 2021-06-12T19:46:54Zoai:revistas.usp.br:article/181418Revistahttps://www.revistas.usp.br/bjps/indexPUBhttps://old.scielo.br/oai/scielo-oai.phpbjps@usp.br||elizabeth.igne@gmail.com2175-97901984-8250opendoar:2021-06-12T19:46:54Brazilian Journal of Pharmaceutical Sciences - Universidade de São Paulo (USP)false
dc.title.none.fl_str_mv Efficacy of secnidazole-diminazene aceturate combination therapy in the late treatment of Trypanosoma brucei brucei infection in dogs
title Efficacy of secnidazole-diminazene aceturate combination therapy in the late treatment of Trypanosoma brucei brucei infection in dogs
spellingShingle Efficacy of secnidazole-diminazene aceturate combination therapy in the late treatment of Trypanosoma brucei brucei infection in dogs
Eke, Ifeanyi Gabriel
Secnidazole
Diminazene aceturate
Combination therapy
Trypanosomosis
Dogs
Relapse
title_short Efficacy of secnidazole-diminazene aceturate combination therapy in the late treatment of Trypanosoma brucei brucei infection in dogs
title_full Efficacy of secnidazole-diminazene aceturate combination therapy in the late treatment of Trypanosoma brucei brucei infection in dogs
title_fullStr Efficacy of secnidazole-diminazene aceturate combination therapy in the late treatment of Trypanosoma brucei brucei infection in dogs
title_full_unstemmed Efficacy of secnidazole-diminazene aceturate combination therapy in the late treatment of Trypanosoma brucei brucei infection in dogs
title_sort Efficacy of secnidazole-diminazene aceturate combination therapy in the late treatment of Trypanosoma brucei brucei infection in dogs
author Eke, Ifeanyi Gabriel
author_facet Eke, Ifeanyi Gabriel
Ezeh, Ikenna Onyema
Ezeudu, Terry Adaeze
Eze, Ukamaka Uchenna
Anaga, Aruh Ottah
Onyeyili, Patrick Azubuike
author_role author
author2 Ezeh, Ikenna Onyema
Ezeudu, Terry Adaeze
Eze, Ukamaka Uchenna
Anaga, Aruh Ottah
Onyeyili, Patrick Azubuike
author2_role author
author
author
author
author
dc.contributor.author.fl_str_mv Eke, Ifeanyi Gabriel
Ezeh, Ikenna Onyema
Ezeudu, Terry Adaeze
Eze, Ukamaka Uchenna
Anaga, Aruh Ottah
Onyeyili, Patrick Azubuike
dc.subject.por.fl_str_mv Secnidazole
Diminazene aceturate
Combination therapy
Trypanosomosis
Dogs
Relapse
topic Secnidazole
Diminazene aceturate
Combination therapy
Trypanosomosis
Dogs
Relapse
description This study evaluated the efficacy of combination therapy of secnidazole-diminazene aceturate (SEC‑DA) in late treatment of dogs experimentally infected with relapsing strain of Trypanosoma brucei brucei. Fifteen dogs were randomly assigned to 5 groups (A – E) of 3 per group. Group A (uninfected untreated), B (infected untreated), C (infected and treated with DA (3.5 mg/kg) IM stat), D (infected and treated with secnidazole (SEC) (100 mg/kg) orally for 5 days and DA (3.5 mg/kg) IM stat), E (infected and treated with SEC (200 mg/kg) orally for 5 days and DA (3.5 mg/kg) IM stat). Dogs were infected intraperitoneally with 5 x 105 trypanosomes and treatment started 14 days post-infection. Data on parasitaemia, hematology and rectal temperature were recorded. Parasitaemia cleared within 3 days in all the SEC-DA treated dogs and there was no relapse parasitaemia. Parasitaemia did not clear in DA monotherapy dogs. All the SEC-DA treated dogs showed significantly (P < 0.05) higher leucocyte counts, red blood cell count, packed cell volume, hemoglobin concentration and lower rectal temperature than DA monotherapy. It was, therefore, concluded that SEC-DA combination is therapeutically more efficacious than DA monotherapy in the late treatment of T.b. brucei infection in dogs.
publishDate 2020
dc.date.none.fl_str_mv 2020-12-09
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://www.revistas.usp.br/bjps/article/view/181418
10.1590/s2175-97902019000318042
url https://www.revistas.usp.br/bjps/article/view/181418
identifier_str_mv 10.1590/s2175-97902019000318042
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv https://www.revistas.usp.br/bjps/article/view/181418/168347
dc.rights.driver.fl_str_mv Copyright (c) 2020 Brazilian Journal of Pharmaceutical Sciences
http://creativecommons.org/licenses/by/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Copyright (c) 2020 Brazilian Journal of Pharmaceutical Sciences
http://creativecommons.org/licenses/by/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Universidade de São Paulo. Faculdade de Ciências Farmacêuticas
publisher.none.fl_str_mv Universidade de São Paulo. Faculdade de Ciências Farmacêuticas
dc.source.none.fl_str_mv Brazilian Journal of Pharmaceutical Sciences; Vol. 56 (2020); e18042
Brazilian Journal of Pharmaceutical Sciences; v. 56 (2020); e18042
Brazilian Journal of Pharmaceutical Sciences; Vol. 56 (2020); e18042
2175-9790
1984-8250
reponame:Brazilian Journal of Pharmaceutical Sciences
instname:Universidade de São Paulo (USP)
instacron:USP
instname_str Universidade de São Paulo (USP)
instacron_str USP
institution USP
reponame_str Brazilian Journal of Pharmaceutical Sciences
collection Brazilian Journal of Pharmaceutical Sciences
repository.name.fl_str_mv Brazilian Journal of Pharmaceutical Sciences - Universidade de São Paulo (USP)
repository.mail.fl_str_mv bjps@usp.br||elizabeth.igne@gmail.com
_version_ 1800222915064496128